Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Factor inhibiting hypoxia-inducible factor 1 (FIH-1) is an asparaginyl hydroxylase enzyme that regulates the activity of hypoxia-inducible factor-1α (HIF-1α), a master transcription factor of the hypoxic response. FIH-1 hydroxylates HIF-1α at Asn-803 in the C-terminal transactivation domain under normoxic conditions, which prevents HIF-1α from recruiting transcriptional coactivators like p300/CBP, thus blocking hypoxia-responsive gene expression in the presence of oxygen[1][3][5][6]. FIH-1 is a non-heme Fe(II)/2-oxoglutarate–dependent dioxygenase and serves as a direct cellular oxygen sensor[1][3][6]. Modulating FIH-1 activity represents a potential strategy for treating ischemic disease and cancer by influencing cellular adaptation to hypoxia[5].
Inhibition of asparaginyl hydroxylase activity increases HIF transcriptional activation by blocking HIF-1α CTAD hydroxylation, allowing interaction with coactivators and expression of hypoxia response genes[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Factor inhibiting hypoxia-inducible factor 1 (FIH-1).